Literature DB >> 12376206

The prognostic significance of the tumour infiltrating lymphocyte count in stage I testicular seminoma managed by surveillance.

C Parker1, M Milosevic, T Panzarella, D Banerjee, M Jewett, C Catton, B Tew-George, M Gospodarowicz, P Warde.   

Abstract

The degree of lymphocytic infiltration is a significant determinant of outcome for a variety of malignancies, but its role in seminoma is unknown. 150 men with stage I testicular seminoma presenting between 1981 and 1993 were managed by surveillance following orchidectomy. The presence of tumour infiltrating lymphocytes (TILs) in each case was classified as high, intermediate or low. At a median follow-up of 9.4 years, 30 of the 150 men developed recurrent seminoma. On univariate analysis, the risk of relapse was associated with age < or =33 years (P=0.002), tumour diameter >6 cm (P=0.03), lymphatic or vascular invasion (P=0.04), tumour invasion of rete testis (P=0.05), and lower TIL count (P=0.02). On multivariate analysis, statistically significant predictors of risk of relapse were age < or =33 years (hazard ratio (HR) 4.6 (95% confidence intervals (CI): 1.7-12.2)) and tumour diameter >6 cm (HR 2.8 (CI: 1.2-6.5)). Lower TIL count was of borderline statistical significance (HR 1.8 (CI: 0.96-3.44)). The functional role of the lymphocytic infiltrate in testicular seminoma warrants further study.

Entities:  

Mesh:

Year:  2002        PMID: 12376206     DOI: 10.1016/s0959-8049(02)00235-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

Review 1.  Biomarkers of disease recurrence in stage I testicular germ cell tumours.

Authors:  Peter Lesko; Michal Chovanec; Michal Mego
Journal:  Nat Rev Urol       Date:  2022-08-26       Impact factor: 16.430

Review 2.  Clinical stage I seminoma: the case for surveillance.

Authors:  Nathan Lawrentschuk; Neil Fleshner
Journal:  World J Urol       Date:  2009-06-11       Impact factor: 4.226

3.  Prognostic features and markers for testicular cancer management.

Authors:  Eddy S Leman; Mark L Gonzalgo
Journal:  Indian J Urol       Date:  2010 Jan-Mar

4.  Canine classical seminoma: a specific malignant type with human classifications is highly correlated with tumor angiogenesis.

Authors:  Jong-Hyuk Kim; Chi-Ho Yu; Ji-Young Yhee; Keum-Soon Im; Na-Hyun Kim; Jung-Hyang Sur
Journal:  BMC Cancer       Date:  2010-05-28       Impact factor: 4.430

5.  Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma.

Authors:  Isabella Lupi; Luca Manetti; Patrizio Caturegli; Michele Menicagli; Mirco Cosottini; Aldo Iannelli; Giovanni Acerbi; Generoso Bevilacqua; Fausto Bogazzi; Enio Martino
Journal:  J Clin Endocrinol Metab       Date:  2009-10-29       Impact factor: 5.958

6.  [Testicular tumors. Predictive factors].

Authors:  G Mikuz
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

7.  Primary tumor size thresholds in stage IA testicular seminoma: Implications for adjuvant therapy after orchiectomy and survival.

Authors:  Mounsif Azizi; Charles C Peyton; David C Boulware; Scott M Gilbert; Wade J Sexton
Journal:  Urol Oncol       Date:  2019-11-05       Impact factor: 3.498

8.  Pure choriocarcinoma of testis with tumor-infiltrating lymphocytes and granulomas.

Authors:  Jai Hyang Go
Journal:  Yonsei Med J       Date:  2006-12-31       Impact factor: 2.759

9.  Pituitary and systemic autoimmunity in a case of intrasellar germinoma.

Authors:  Angelika Gutenberg; Jennifer J Bell; Isabella Lupi; Shey-Cherng Tzou; Melissa A Landek-Salgado; Hiroaki Kimura; Jack Su; Lefkothea P Karaviti; Roberto Salvatori; Patrizio Caturegli
Journal:  Pituitary       Date:  2009-05-26       Impact factor: 4.107

10.  Outcome of patients with HIV-related germ cell tumours: a case-control study.

Authors:  T Powles; M Bower; J Shamash; J Stebbing; J Ong; G Daugaard; A De Ruiter; M Johnson; M Fisher; J Anderson; M Nelson; B Gazzard; T Oliver
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.